FY2026 Earnings Forecast for Geron Issued By Leerink Partnrs

Geron Co. (NASDAQ:GERNFree Report) – Investment analysts at Leerink Partnrs lifted their FY2026 earnings estimates for Geron in a research report issued to clients and investors on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of $0.36 for the year, up from their prior estimate of $0.33. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

A number of other brokerages also recently issued reports on GERN. Leerink Partners assumed coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday. Scotiabank assumed coverage on shares of Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. Finally, Barclays upgraded Geron to a “strong-buy” rating in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron presently has an average rating of “Moderate Buy” and an average price target of $7.15.

Check Out Our Latest Stock Report on Geron

Geron Stock Performance

NASDAQ:GERN opened at $3.99 on Wednesday. The stock has a 50-day simple moving average of $4.09 and a two-hundred day simple moving average of $4.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52-week low of $1.64 and a 52-week high of $5.34. The firm has a market capitalization of $2.41 billion, a PE ratio of -12.47 and a beta of 0.51.

Geron (NASDAQ:GERNGet Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year.

Institutional Investors Weigh In On Geron

Several large investors have recently bought and sold shares of GERN. Franklin Resources Inc. increased its stake in Geron by 461.4% during the third quarter. Franklin Resources Inc. now owns 79,923 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 65,687 shares during the last quarter. World Investment Advisors LLC raised its holdings in Geron by 10,151.4% during the 3rd quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock valued at $4,674,000 after buying an additional 1,019,510 shares during the period. Geode Capital Management LLC lifted its position in Geron by 1.8% in the third quarter. Geode Capital Management LLC now owns 13,067,999 shares of the biopharmaceutical company’s stock worth $59,339,000 after buying an additional 231,178 shares during the last quarter. Barclays PLC boosted its stake in Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after buying an additional 694,931 shares during the period. Finally, Main Management ETF Advisors LLC bought a new position in Geron during the third quarter valued at $895,000. Institutional investors own 73.71% of the company’s stock.

About Geron

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Recommended Stories

Earnings History and Estimates for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.